circulating tumor DNA Jul 29, 2022 Stakeholders Urge Collaboration to Prove ctDNA as Regulatory Endpoint for Early Cancer Drugs Premium Jul 22, 2022 Lung Cancer MRD Study Bolsters Validity Evidence, Suggests Longitudinal Test Cutoff Premium Jul 20, 2022 Treatment-Resistant Prostate Cancer Clues Drawn From Circulating Tumor DNA Dynamics Jul 8, 2022 BillionToOne, UCSD Partner to Assess New Liquid Biopsy Assays in Lung Cancer Jul 7, 2022 ESMO Releases Guidelines for Liquid Biopsy Testing in Cancer Patients Jun 16, 2022 Treadwell Therapeutics Begins Trial of CFI-402257 in Patients With Solid Tumors, Breast Cancer Jun 8, 2022 New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur Premium Jun 7, 2022 Circulating Tumor DNA Utility in Post-Surgery Stage II Colon Cancer Cemented by New Data Premium Jun 4, 2022 At ASCO, Biomarker Strategies Show Potential for Guiding Metastatic Pancreatic Cancer Treatment Premium May 9, 2022 Artemis DNA to Provide Datar Cancer Genetics Liquid Biopsy Tests in the US, Vietnam Under $250M Deal May 9, 2022 Delfi Diagnostics Begins Second, Larger Prospective Lung Cancer Screening Trial Apr 20, 2022 Proof-of-Principle Study Points to Possibility of Monitoring Pediatric ALL With Plasma Samples Apr 13, 2022 Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests Premium Mar 11, 2022 Tyra Biosciences, xCures Launch Real-World Biomarker Study in FGFR-Mutated Bladder Cancer Mar 9, 2022 Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data Feb 18, 2022 PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions Premium Feb 18, 2022 Invitae Launches Study to Generate Real-World Data on Personalized MRD Test Across Tumor Types Premium Feb 17, 2022 New Data Further Validates Inivata's MRD Test as Company Prepares Commercial Launch Premium Jan 26, 2022 Early Detection, MRD Test Data Get Optimistic Reception From GI Oncologists at ASCO Meeting Premium Dec 10, 2021 SABCS Studies Show Promise of ctDNA Analysis in Individualizing CDK4/6 Inhibitor, Endocrine Therapy Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
